BerGenBio will be hosting a live webcast and Q&A session at 10:00 CEST today to provide information on the ACCORD (ACcelerating COVID-19 Research & Development platform) study where bemcentinib has been selected as the first potential treatment to be fast-tracked in this new study.
Webcast link: https://channel.royalcast.com/webcast/hegnarmedia/20200429_9/
Dial-in numbers:
– NO: +47 2195 6342
– UK: +44 203 769 6819
– US: +1 646 787 0157
PIN: 569168
